Navigation Links
Genalyte Awarded $500,000 SBIR Grant To Develop Multiplexed Assays For Early Detection And Monitoring Of Type 1 Diabetes
Date:12/11/2012

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Genalyte, Inc. today announced that it has been awarded a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of Type 1 diabetes that will run on Genalyte's innovative MaverickTMDetection System.  The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.  Genalyte's novel multiplexing technology simultaneously screens for the detection of multiple autoantibodies and other proteins using a one-step, 15-minute process. 

The SBIR-funded program initially will create a basic multiplexed assay to detect autoimmune response for known targets for Type 1 diabetes.  It will then expand the approach to profile autoantibody response by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.

"The pioneering work of the late Dr. Eisenbarth and others established that the development of Type 1 diabetes is an incremental process, as rogue elements of the immune system over time compromise and eventually destroy the pancreatic islet cells that produce insulin," noted Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.  "The unique capabilities of our Maverick multiplexed detection platform have the potential to provide researchers and clinicians with the tools to detect and track this process from a very early stage, when therapeutic intervention to interrupt the process could be feasible."

Once the autoantibody panels have been developed and tested, they will be refined and validated using samples from patients with Type 1 diabetes.  Genalyte expects to collaborate on this phase of the project with researchers from Dr. Eisenbarth's laboratory at the Barbara Davis Diabetes Center of the University of Colorado School of Medicine in Denver.

Dr. Gleeson added, "From early on we envisioned that the unprecedented multiplexing capabilities of our Maverick technology would make it possible to change the way that certain diseases are diagnosed and treated.  We are delighted that NIDDK is supporting development of these assays that have the potential to make this goal a reality for the millions of individuals at risk of Type 1 diabetes."

Genalyte's Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.  The Maverick system's one-step approach automates the washes, incubations, reagent processing and other steps needed for the analysis.  Semi-quantitative results are reported for each analyte, eliminating the need for reflex testing.  The Maverick platform has a large dynamic range and excellent sensitivity, with outstanding reproducibility.

The Maverick Detection System and its ENA 4 and ENA 6 Assay Kits are currently commercially available.  They simultaneously screen for several of the most common antibodies found in autoimmune connective tissue disorders, such as lupus (SLE), Sjogren's syndrome, and scleroderma.  The assay results are highly reproducible, show excellent correlation to ELISA and are up to ten times more sensitive.  Assay kits for advanced SLE testing, rheumatoid arthritis and Type I diabetes are available under the Genalyte Technology Access program. 

For more information about the Maverick platform and Genalyte's new Custom Chip Spotting Service, visit www.genalyte.com.  Maverick assays are currently available for research use only.

About Genalyte
Founded in 2007, Genalyte, Inc. is commercializing the MaverickTM detection platform based on the company's revolutionary Microring Sensor TechnologyTM a new approach to multiplexing that leverages advances in silicon photonics to reduce or eliminate sample preparation, provide scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieve excellent sensitivity and up to eight logs of dynamic range.Contacts:Genalyte, Inc.

Media:Martin Gleeson, PhD

BLL Partners, LLCChief Scientific Officer

Barbara Lindheim+1 858 750-4470

+1 212 584-2276martin@genalyte.com

blindheim@bllbiopartners.com


'/>"/>
SOURCE Genalyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Florida Blue Awarded Certified Center of Excellence by BenchmarkPortal for Second Consecutive Year
2. Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
3. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
4. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
7. Breast Cancer Survivor Awarded Top Prize In 2012 Oncology On Canvas(SM) Art Competition
8. New Snoring Therapy Awarded The Prestigious Spark Award
9. Harrisvaccines Awarded Vaccine Product Licensure
10. Healionics Awarded $900k Grant from NIH
11. Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):